Colon-Targeted Trans-Cinnamic Acid Ameliorates Rat Colitis by Activating GPR109A

Area of Science:

• Pharmacology
• Gastroenterology
• Drug Delivery

Background:

• Inflammatory bowel disease (IBD) requires effective treatments targeting the colon.
• Current IBD therapies like sulfasalazine (SSZ) have limitations.
• Trans-cinnamic acid (tCA) shows potential anti-colitic activity.

Purpose of the Study:

• To design and synthesize colon-targeted tCA conjugates.
• To evaluate the anti-colitic efficacy of these conjugates in a rat model.
• To elucidate the mechanism of action involving GPR109A.

Main Methods:

• Synthesis of tCA conjugates with glutamic acid (tCA-GA) and aspartic acid (tCA-AA).
• Assessment of colon-targeting efficiency and in vivo anti-colitic activity using a dinitrobenzenesulfonic acid-induced rat colitis model.
• In vitro G protein-coupled receptor 109A (GPR109A) agonism assay and antagonist studies.

Main Results:

• tCA-GA and tCA-AA demonstrated reduced Caco-2 cell permeability and conversion to tCA in the cecum, with tCA-GA showing higher efficiency.
• Oral administration of tCA-GA resulted in greater tCA delivery to the cecum and superior anti-colitic effects compared to tCA and SSZ.
• tCA was identified as a full agonist of GPR109A (EC50: 530 µM), and its anti-colitic effects were mediated via GPR109A activation.

Conclusions:

• Colon-targeted tCA, specifically tCA-GA, potentiates the anti-colitic activity of tCA through effective GPR109A activation in the inflamed colon.
• This targeted delivery strategy enhances therapeutic efficacy, suggesting potential superiority over existing treatments for IBD.
• tCA-GA represents a promising novel therapeutic agent for managing colitis.